Valuation: GlucoTrack, Inc.

Market Cap 379K 342K 316K 285K 540K 35.54M 553K 3.78M 1.51M 19.03M 1.42M 1.39M 60.57M P/E 2024 *
-
P/E 2025 -0.12x
Enterprise Value -3.56M -3.21M -2.96M -2.68M -5.07M -334M -5.19M -35.51M -14.15M -179M -13.35M -13.07M -569M EV / Sales 2024
-
EV / Sales 2025 -
Free-Float
96.7%
Yield 2024 *
-
Yield 2025 -
1 week+203.76%
Current month+71.60%
1 month-32.52%
3 months-88.50%
6 months-94.21%
Current year-98.80%
1 week 0.28
Extreme 0.28
1.39
1 month 0.28
Extreme 0.28
2.5
Current year 0.28
Extreme 0.28
127.2
1 year 0.28
Extreme 0.28
207
3 years 0.28
Extreme 0.28
178,198.57
5 years 0.28
Extreme 0.28
872,993.02
10 years 0.28
Extreme 0.28
14,038,371.55
Manager TitleAgeSince
Chief Executive Officer 55 2026-07-13
Director of Finance/CFO 66 2025-01-27
Chief Operating Officer - 2025-01-31
Director TitleAgeSince
Director/Board Member 56 2023-08-24
Chairman 64 2024-02-12
Director/Board Member 78 2024-06-13
Date Insider Type Main position Quantity % Market Cap. Importance
3/26/25 Free

Director

4,490 0.0431%
3/25/25 Free

Director

8,747 0.0840%
3/25/25 Free

Director

5,473 0.0526%
Change 5-day change 1-year change 3-year change Capi.($)
-.--%+203.76%-99.17%-100.00% 379K
-1.06%+9.92%+59.12%+68.61% 68.32B
+1.30%+7.41%+14.79%+90.26% 60.26B
+0.39%+0.30%+20.04%+97.74% 55.86B
-0.74%+11.45%+22.52%+111.74% 48.43B
+0.59%+5.10%+26.87%+43.15% 45.34B
-6.38%-8.90%+183.92%+825.88% 41.76B
+1.97%+9.00%+25.20%+50.98% 34.5B
-0.56%-0.48%+85.57%+57.71% 33.8B
-1.49%+13.52%+43.09%+0.06% 25.96B
Average -0.62%+6.96%+38.20%+124.61% 41B
Weighted average by Cap. -0.60%+4.04%+50.50%+147.63%

Financials

2024 2025
Net sales - -
Net income -22.6M -20.37M -18.82M -17.01M -32.18M -2.12B -32.98M -226M -89.88M -1.14B -84.81M -83M -3.61B -19.39M -17.47M -16.14M -14.59M -27.61M -1.82B -28.29M -193M -77.12M -974M -72.76M -71.22M -3.1B
Net Debt -5.35M -4.82M -4.45M -4.03M -7.62M -502M -7.81M -53.39M -21.28M -269M -20.08M -19.65M -855M -3.94M -3.55M -3.28M -2.96M -5.61M -369M -5.75M -39.29M -15.66M -198M -14.78M -14.46M -629M
Projected Income Statement - Annual - GlucoTrack, Inc.
Logo GlucoTrack, Inc.
Glucotrack, Inc. is focused on the design, development, and commercialization of technologies for people with diabetes. The Company is engaged in developing a long-term Implantable Continuous Blood Glucose Monitor (CBGM) for people living with Type 1 diabetes and insulin-dependent Type 2 diabetes. Its CBGM is a long-term, implantable system that continually measures blood glucose levels with a sensor longevity of 3 years, no on-body wearable component and with minimal calibration. Its CBGM technology allows for a less burdensome approach to glucose monitoring. It has also completed four animal studies with evolving prototype systems, all four of which consistently demonstrated a simple implant procedure, functionality, and safety. The Company has also demonstrated continuous glucose sensing in the epidural space via two additional animal trials, both of which demonstrated a simple implant procedure, functionality, and safety.
Employees
15
Date Price Change Volume
26-11-10 US$0.3200 -5.88% 28,504
26-11-09 US$0.3400 +13.33% 15,026
26-11-06 US$0.3000 -21.05% 41,325
26-11-05 US$0.3800 -5.00% 39,104
26-11-04 US$0.4000 -12.59% 20,297
  1. Stock Market
  2. Stocks
  3. GCTK Stock